- Home
- WCC vs ROIV Comparison
WCC vs ROIV Comparison
Compare WCC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCC
- ROIV
- Stock Information
- Founded
- WCC 1922
- ROIV 2014
- Country
- WCC United States
- ROIV United Kingdom
- Employees
- WCC N/A
- ROIV N/A
- Industry
- WCC Telecommunications Equipment
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- WCC Consumer Discretionary
- ROIV Health Care
- Exchange
- WCC Nasdaq
- ROIV Nasdaq
- Market Cap
- WCC 9.8B
- ROIV 8.4B
- IPO Year
- WCC 1999
- ROIV N/A
- Fundamental
- Price
- WCC $210.18
- ROIV $12.42
- Analyst Decision
- WCC Buy
- ROIV Strong Buy
- Analyst Count
- WCC 7
- ROIV 9
- Target Price
- WCC $208.86
- ROIV $17.69
- AVG Volume (30 Days)
- WCC 816.6K
- ROIV 4.5M
- Earning Date
- WCC 10-31-2024
- ROIV 11-12-2024
- Dividend Yield
- WCC 0.79%
- ROIV N/A
- EPS Growth
- WCC N/A
- ROIV N/A
- EPS
- WCC 12.46
- ROIV 5.89
- Revenue
- WCC $21,792,500,000.00
- ROIV $129,128,999.00
- Revenue This Year
- WCC N/A
- ROIV $48.37
- Revenue Next Year
- WCC $3.15
- ROIV $13.76
- P/E Ratio
- WCC $16.67
- ROIV $2.01
- Revenue Growth
- WCC N/A
- ROIV 145.68
- 52 Week Low
- WCC $132.37
- ROIV $8.61
- 52 Week High
- WCC $213.75
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- WCC 63.93
- ROIV 56.39
- Support Level
- WCC $200.48
- ROIV $11.05
- Resistance Level
- WCC $206.65
- ROIV $11.97
- Average True Range (ATR)
- WCC 5.97
- ROIV 0.31
- MACD
- WCC -0.44
- ROIV 0.02
- Stochastic Oscillator
- WCC 79.82
- ROIV 83.26
About WCC WESCO International Inc.
Wesco International is an industrial distributor that has three reportable segments, electrical and electronic solutions, communications and security solutions, and utility and broadband solutions. The company offers more than 1.5 million products to its 140,000 active customers through a distribution network of 800 branches, warehouses, and sales offices, including 43 distribution centers. Wesco generates approximately 74% of its sales in the United States, but it has a global reach, with operations in 50 other countries.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.